GW-493838

GW‑493838 is a small molecule investigational drug developed by GlaxoSmithKline as a selective adenosine A1 receptor agonist. It was studied primarily for the treatment of neuropathic pain and dyslipidemia. The compound reached phase II clinical trials for both indications but development was discontinued after these studies. Its mechanism of action involves activation of the adenosine A1 receptor (A1AR), which is thought to mediate analgesic effects in neuropathic pain and potentially modulate lipid metabolism[3][4][5][7].

Other names

(2S,3S,4R,5R)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(6-(4-chloro-2-fluoro-anilino)purin-9-yl)tetrahydrofuran-3,4-diolUNII 93OG0JL22OUNII93OG0JL22OUNII-93OG0JL22OCAS 253124–46–8